{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:29:43Z","timestamp":1761863383574},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.amjcard.2015.01.551","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T01:02:42Z","timestamp":1422925362000},"page":"1154-1161","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Cangrelor"],"prefix":"10.1016","volume":"115","author":[{"given":"Thibault","family":"Lhermusier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2015.01.551_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/erc.09.101","article-title":"Cangrelor: a review on its mechanism of action and clinical development","volume":"7","author":"Ferreiro","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2015.01.551_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF03086246","article-title":"Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects","volume":"17","author":"Bouman","year":"2009","journal-title":"Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found"},{"key":"10.1016\/j.amjcard.2015.01.551_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","article-title":"Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect","volume":"121","author":"Steinhubl","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.amjcard.2015.01.551_bib7","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib8","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.01.551_bib11","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.01.551_bib12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2015.01.551_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2015.01.551_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2012.08.018","article-title":"Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes","volume":"6","author":"Brener","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2015.01.551_bib15","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.01.551_bib16","unstructured":"The Medicines Company. Briefing Document. Cangrelor for injection, for the meeting of the Cardiovascular and Renal Drugs Advisory Committee. Presented February 12, 2010, at Silver Spring, MD Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM385236.pdf. Accessed on February 20, 2015."},{"key":"10.1016\/j.amjcard.2015.01.551_bib17","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2015.01.551_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.01.551_bib19","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.01.551_bib20","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","volume":"54","author":"Kushner","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.01.551_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.01.551_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.01.551_bib23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2146\/ajhp100008","article-title":"Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions","volume":"67","author":"Dean","year":"2010","journal-title":"Am J Health-syst Pharm AJHP Off J Am Soc Health-syst Pharm"},{"key":"10.1016\/j.amjcard.2015.01.551_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacc.2013.10.022","volume":"63","author":"G\u00e9n\u00e9reux","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.01.551_bib25","unstructured":"US Food and Drug Administration. FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee. Presented February 12, 2014, at Silver Spring, MD. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM385234.pdf. Accessed on February 20, 2015."},{"key":"10.1016\/j.amjcard.2015.01.551_bib26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry","volume":"53","author":"van Werkum","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.01.551_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jtcvs.2011.01.069","article-title":"Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies","volume":"143","author":"Biancari","year":"2012","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjcard.2015.01.551_bib28","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/eurheartj\/ehr151","article-title":"Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies","volume":"32","author":"Nijjer","year":"2011","journal-title":"Eur Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915006463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915006463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T14:24:12Z","timestamp":1537885452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914915006463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0002914915006463"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.01.551","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Cangrelor","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.01.551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}